Concepts (222)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carnosine | 6 | 2014 | 8 | 1.740 |
Why?
|
| Antimicrobial Cationic Peptides | 6 | 2021 | 34 | 1.630 |
Why?
|
| Blood Proteins | 6 | 2021 | 68 | 1.620 |
Why?
|
| Alzheimer Disease | 4 | 2022 | 220 | 1.490 |
Why?
|
| Wound Healing | 3 | 2020 | 125 | 1.170 |
Why?
|
| Corneal Injuries | 3 | 2020 | 12 | 1.160 |
Why?
|
| Cataract | 4 | 2011 | 25 | 1.010 |
Why?
|
| Amyloid beta-Peptides | 3 | 2022 | 49 | 0.910 |
Why?
|
| Toll-Like Receptor 4 | 2 | 2022 | 72 | 0.830 |
Why?
|
| Neutrophils | 2 | 2021 | 181 | 0.780 |
Why?
|
| Carrier Proteins | 5 | 2015 | 252 | 0.780 |
Why?
|
| Epithelium, Corneal | 2 | 2020 | 14 | 0.780 |
Why?
|
| Oxidoreductases | 4 | 2008 | 57 | 0.780 |
Why?
|
| Aldehydes | 3 | 2012 | 55 | 0.780 |
Why?
|
| Prodrugs | 3 | 2011 | 30 | 0.710 |
Why?
|
| Retinal Dehydrogenase | 2 | 2012 | 10 | 0.690 |
Why?
|
| Calgranulin B | 1 | 2020 | 17 | 0.670 |
Why?
|
| Peptide Fragments | 2 | 2021 | 202 | 0.670 |
Why?
|
| Ophthalmic Solutions | 4 | 2020 | 27 | 0.640 |
Why?
|
| Hydrazines | 2 | 2009 | 13 | 0.620 |
Why?
|
| Retina | 4 | 2012 | 436 | 0.620 |
Why?
|
| Histidine | 2 | 2009 | 52 | 0.610 |
Why?
|
| Mice | 13 | 2022 | 4654 | 0.580 |
Why?
|
| Animals | 21 | 2022 | 10423 | 0.560 |
Why?
|
| Antioxidants | 2 | 2009 | 223 | 0.550 |
Why?
|
| Retinal Degeneration | 3 | 2012 | 151 | 0.490 |
Why?
|
| Proteins | 5 | 2004 | 252 | 0.470 |
Why?
|
| Pseudomonas Infections | 1 | 2014 | 25 | 0.460 |
Why?
|
| Drug Delivery Systems | 3 | 2011 | 225 | 0.440 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2014 | 71 | 0.430 |
Why?
|
| Eye Proteins | 2 | 2012 | 205 | 0.420 |
Why?
|
| Alcohol Oxidoreductases | 3 | 2011 | 34 | 0.420 |
Why?
|
| Oxidative Stress | 5 | 2012 | 668 | 0.410 |
Why?
|
| Lubricants | 2 | 2009 | 3 | 0.390 |
Why?
|
| Cathepsin G | 2 | 2022 | 6 | 0.380 |
Why?
|
| Eye Diseases | 1 | 2011 | 31 | 0.360 |
Why?
|
| Anti-Bacterial Agents | 1 | 2014 | 524 | 0.330 |
Why?
|
| Photoreceptor Cells | 1 | 2009 | 36 | 0.320 |
Why?
|
| Humans | 19 | 2022 | 28097 | 0.320 |
Why?
|
| Diabetes Complications | 1 | 2009 | 66 | 0.300 |
Why?
|
| Cell Line | 4 | 2020 | 696 | 0.280 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2008 | 123 | 0.270 |
Why?
|
| Administration, Ophthalmic | 2 | 2020 | 8 | 0.260 |
Why?
|
| Chromatography, High Pressure Liquid | 4 | 2012 | 131 | 0.260 |
Why?
|
| Mice, Inbred C57BL | 5 | 2020 | 1576 | 0.260 |
Why?
|
| Light | 4 | 2011 | 118 | 0.250 |
Why?
|
| Dark Adaptation | 1 | 2005 | 11 | 0.240 |
Why?
|
| Lipid Peroxidation | 3 | 2009 | 47 | 0.240 |
Why?
|
| Photoreceptor Cells, Vertebrate | 1 | 2006 | 67 | 0.240 |
Why?
|
| Receptor, Insulin | 3 | 2001 | 93 | 0.240 |
Why?
|
| Signal Transduction | 6 | 2014 | 1435 | 0.230 |
Why?
|
| Aging | 3 | 2014 | 968 | 0.220 |
Why?
|
| Mice, Knockout | 4 | 2009 | 848 | 0.220 |
Why?
|
| src Homology Domains | 3 | 2000 | 31 | 0.220 |
Why?
|
| Aldehyde Reductase | 1 | 2003 | 7 | 0.210 |
Why?
|
| Female | 8 | 2020 | 15156 | 0.200 |
Why?
|
| Retinal Rod Photoreceptor Cells | 3 | 2011 | 91 | 0.200 |
Why?
|
| Trypan Blue | 1 | 2022 | 2 | 0.200 |
Why?
|
| Receptor for Advanced Glycation End Products | 1 | 2022 | 12 | 0.200 |
Why?
|
| Disease Models, Animal | 4 | 2020 | 1461 | 0.200 |
Why?
|
| Calcium-Binding Proteins | 1 | 2022 | 62 | 0.200 |
Why?
|
| RNA, Messenger | 4 | 2008 | 659 | 0.190 |
Why?
|
| Neuroprotective Agents | 2 | 2012 | 52 | 0.190 |
Why?
|
| Cornea | 2 | 2014 | 68 | 0.190 |
Why?
|
| Aged, 80 and over | 4 | 2015 | 2021 | 0.180 |
Why?
|
| Leukocyte Elastase | 1 | 2021 | 6 | 0.180 |
Why?
|
| In Vitro Techniques | 1 | 2021 | 241 | 0.170 |
Why?
|
| Adaptor Proteins, Signal Transducing | 3 | 2004 | 163 | 0.170 |
Why?
|
| Immunohistochemistry | 4 | 2014 | 463 | 0.170 |
Why?
|
| Electroretinography | 3 | 2012 | 179 | 0.170 |
Why?
|
| Chromatography, Liquid | 1 | 2020 | 77 | 0.160 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2020 | 257 | 0.160 |
Why?
|
| Administration, Topical | 2 | 2009 | 30 | 0.160 |
Why?
|
| Transcription Factors | 1 | 2003 | 520 | 0.160 |
Why?
|
| Glycation End Products, Advanced | 2 | 2009 | 17 | 0.160 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2020 | 114 | 0.160 |
Why?
|
| Insulin | 3 | 2004 | 315 | 0.160 |
Why?
|
| Molecular Sequence Data | 5 | 2004 | 1054 | 0.160 |
Why?
|
| Cross-Over Studies | 2 | 2009 | 134 | 0.150 |
Why?
|
| Glycosylation | 2 | 2009 | 70 | 0.150 |
Why?
|
| Eosinophil Granule Proteins | 1 | 2018 | 5 | 0.150 |
Why?
|
| Neurogenic Inflammation | 1 | 2018 | 3 | 0.150 |
Why?
|
| Liposomes | 2 | 2009 | 145 | 0.150 |
Why?
|
| Double-Blind Method | 2 | 2009 | 417 | 0.150 |
Why?
|
| Mice, Inbred BALB C | 2 | 2009 | 276 | 0.140 |
Why?
|
| Adaptor Proteins, Vesicular Transport | 1 | 1997 | 31 | 0.140 |
Why?
|
| Phosphoproteins | 1 | 1997 | 120 | 0.130 |
Why?
|
| Aged | 4 | 2015 | 5400 | 0.130 |
Why?
|
| Retinoids | 2 | 2007 | 38 | 0.130 |
Why?
|
| Immunoblotting | 2 | 2008 | 124 | 0.130 |
Why?
|
| Phosphorylation | 5 | 2004 | 578 | 0.130 |
Why?
|
| In Situ Hybridization | 2 | 2008 | 34 | 0.130 |
Why?
|
| Amino Acid Sequence | 4 | 2004 | 692 | 0.120 |
Why?
|
| Pyramidal Cells | 1 | 2015 | 9 | 0.120 |
Why?
|
| Mutation | 3 | 2009 | 847 | 0.120 |
Why?
|
| Apoptosis | 2 | 2009 | 775 | 0.120 |
Why?
|
| Transcription, Genetic | 2 | 2008 | 403 | 0.120 |
Why?
|
| Enzyme Activation | 2 | 2013 | 267 | 0.110 |
Why?
|
| Protein Kinase C-delta | 1 | 2014 | 6 | 0.110 |
Why?
|
| Eye Injuries | 1 | 2014 | 11 | 0.110 |
Why?
|
| Liver | 3 | 2005 | 440 | 0.110 |
Why?
|
| Telomere Shortening | 1 | 2014 | 4 | 0.110 |
Why?
|
| Patents as Topic | 1 | 2014 | 5 | 0.110 |
Why?
|
| Telomere Homeostasis | 1 | 2014 | 10 | 0.110 |
Why?
|
| HEK293 Cells | 1 | 2014 | 187 | 0.110 |
Why?
|
| Dipeptides | 1 | 2014 | 22 | 0.110 |
Why?
|
| Inflammation Mediators | 1 | 2015 | 165 | 0.110 |
Why?
|
| Rejuvenation | 1 | 2014 | 26 | 0.110 |
Why?
|
| Male | 5 | 2015 | 13491 | 0.110 |
Why?
|
| Imidazoles | 1 | 2014 | 63 | 0.110 |
Why?
|
| Chemotaxis | 1 | 2013 | 28 | 0.110 |
Why?
|
| Binding Sites | 3 | 2000 | 353 | 0.110 |
Why?
|
| Protein Kinase C | 1 | 2013 | 73 | 0.110 |
Why?
|
| Middle Aged | 3 | 2009 | 7138 | 0.110 |
Why?
|
| Life Style | 1 | 2014 | 89 | 0.100 |
Why?
|
| Cell Movement | 1 | 2014 | 373 | 0.100 |
Why?
|
| BALB 3T3 Cells | 1 | 2012 | 5 | 0.100 |
Why?
|
| Molecular Targeted Therapy | 1 | 2014 | 135 | 0.100 |
Why?
|
| Rats | 4 | 2011 | 1576 | 0.090 |
Why?
|
| Vitreoretinopathy, Proliferative | 1 | 2011 | 3 | 0.090 |
Why?
|
| Cyclic N-Oxides | 1 | 2011 | 26 | 0.090 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2011 | 25 | 0.090 |
Why?
|
| cis-trans-Isomerases | 1 | 2011 | 27 | 0.090 |
Why?
|
| Rhodopsin | 1 | 2011 | 40 | 0.090 |
Why?
|
| Mass Spectrometry | 1 | 2012 | 191 | 0.090 |
Why?
|
| Cells, Cultured | 4 | 2015 | 985 | 0.090 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2008 | 328 | 0.090 |
Why?
|
| Retinal Cone Photoreceptor Cells | 2 | 2008 | 126 | 0.090 |
Why?
|
| Base Sequence | 2 | 2003 | 586 | 0.080 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2009 | 607 | 0.080 |
Why?
|
| Recombinant Fusion Proteins | 3 | 2001 | 233 | 0.080 |
Why?
|
| Delayed-Action Preparations | 1 | 2009 | 43 | 0.080 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2011 | 385 | 0.080 |
Why?
|
| Aminooxyacetic Acid | 1 | 2009 | 1 | 0.080 |
Why?
|
| Ophthalmoscopy | 1 | 2009 | 6 | 0.080 |
Why?
|
| Cloning, Molecular | 2 | 2000 | 208 | 0.080 |
Why?
|
| Contact Lenses | 1 | 2009 | 6 | 0.080 |
Why?
|
| Biological Availability | 1 | 2009 | 44 | 0.080 |
Why?
|
| Phytotherapy | 1 | 2008 | 22 | 0.080 |
Why?
|
| Ophthalmologic Surgical Procedures | 1 | 2009 | 23 | 0.080 |
Why?
|
| Drug Synergism | 1 | 2009 | 104 | 0.080 |
Why?
|
| Drug Administration Schedule | 1 | 2009 | 224 | 0.070 |
Why?
|
| Rabbits | 1 | 2009 | 277 | 0.070 |
Why?
|
| Visual Acuity | 1 | 2009 | 111 | 0.070 |
Why?
|
| Radiation Injuries, Experimental | 1 | 2008 | 31 | 0.070 |
Why?
|
| Curcumin | 1 | 2008 | 69 | 0.070 |
Why?
|
| Macular Degeneration | 1 | 2008 | 84 | 0.070 |
Why?
|
| Phenotype | 1 | 2009 | 681 | 0.070 |
Why?
|
| Gene Expression Profiling | 2 | 2008 | 453 | 0.070 |
Why?
|
| Kinetics | 2 | 2005 | 545 | 0.070 |
Why?
|
| Prospective Studies | 1 | 2009 | 1248 | 0.060 |
Why?
|
| Catalysis | 2 | 2003 | 133 | 0.060 |
Why?
|
| Neomycin | 1 | 2005 | 7 | 0.060 |
Why?
|
| beta-Galactosidase | 1 | 2005 | 24 | 0.060 |
Why?
|
| Drug Resistance | 1 | 2005 | 42 | 0.060 |
Why?
|
| Testis | 1 | 2005 | 39 | 0.060 |
Why?
|
| Homeostasis | 1 | 2005 | 118 | 0.060 |
Why?
|
| Calcium | 1 | 2005 | 235 | 0.050 |
Why?
|
| GRB7 Adaptor Protein | 2 | 2001 | 4 | 0.050 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2003 | 133 | 0.050 |
Why?
|
| DNA | 1 | 2005 | 374 | 0.050 |
Why?
|
| Gene Expression | 1 | 2005 | 417 | 0.050 |
Why?
|
| Models, Biological | 1 | 2006 | 466 | 0.050 |
Why?
|
| DNA Primers | 1 | 2003 | 147 | 0.050 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 2 | 2004 | 50 | 0.050 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2003 | 168 | 0.050 |
Why?
|
| CHO Cells | 2 | 2001 | 96 | 0.050 |
Why?
|
| Cricetinae | 2 | 2001 | 129 | 0.050 |
Why?
|
| Two-Hybrid System Techniques | 1 | 2000 | 32 | 0.040 |
Why?
|
| Yeasts | 1 | 2000 | 7 | 0.040 |
Why?
|
| COS Cells | 1 | 2000 | 49 | 0.040 |
Why?
|
| Protein Binding | 2 | 2001 | 658 | 0.040 |
Why?
|
| Placenta | 1 | 2000 | 78 | 0.040 |
Why?
|
| Sequence Homology | 1 | 1998 | 9 | 0.040 |
Why?
|
| Phosphotyrosine | 1 | 1998 | 18 | 0.040 |
Why?
|
| Kidney | 1 | 2000 | 286 | 0.040 |
Why?
|
| Asparagine | 1 | 1997 | 7 | 0.040 |
Why?
|
| Src Homology 2 Domain-Containing, Transforming Protein 1 | 1 | 1997 | 10 | 0.040 |
Why?
|
| Insulin Receptor Substrate Proteins | 1 | 1997 | 23 | 0.040 |
Why?
|
| Shc Signaling Adaptor Proteins | 1 | 1997 | 8 | 0.030 |
Why?
|
| Blotting, Western | 2 | 2013 | 514 | 0.030 |
Why?
|
| Tyrosine | 1 | 1997 | 92 | 0.030 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 1997 | 132 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 1 | 1998 | 369 | 0.030 |
Why?
|
| Pregnancy | 1 | 2000 | 1191 | 0.030 |
Why?
|
| Primary Cell Culture | 1 | 2015 | 28 | 0.030 |
Why?
|
| Parietal Lobe | 1 | 2015 | 27 | 0.030 |
Why?
|
| Temporal Lobe | 1 | 2015 | 32 | 0.030 |
Why?
|
| Up-Regulation | 1 | 2015 | 246 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2015 | 247 | 0.030 |
Why?
|
| Microscopy, Confocal | 1 | 2013 | 113 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2015 | 722 | 0.030 |
Why?
|
| Glycoproteins | 1 | 2013 | 122 | 0.030 |
Why?
|
| Immunity, Innate | 1 | 2014 | 226 | 0.020 |
Why?
|
| Acyltransferases | 1 | 2011 | 24 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2011 | 551 | 0.020 |
Why?
|
| Cytoprotection | 1 | 2008 | 24 | 0.020 |
Why?
|
| Rats, Wistar | 1 | 2008 | 151 | 0.020 |
Why?
|
| Transcriptional Activation | 1 | 2008 | 86 | 0.020 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2008 | 102 | 0.020 |
Why?
|
| Phosphatidylcholine-Sterol O-Acyltransferase | 1 | 2007 | 1 | 0.020 |
Why?
|
| Retinol O-Fatty-Acyltransferase | 1 | 2007 | 1 | 0.020 |
Why?
|
| Retinaldehyde | 1 | 2007 | 7 | 0.020 |
Why?
|
| NF-kappa B | 1 | 2008 | 191 | 0.020 |
Why?
|
| Young Adult | 1 | 2015 | 2733 | 0.020 |
Why?
|
| Esters | 1 | 2007 | 12 | 0.020 |
Why?
|
| Vitamin A | 1 | 2007 | 26 | 0.020 |
Why?
|
| Photic Stimulation | 1 | 2007 | 67 | 0.020 |
Why?
|
| Oxidation-Reduction | 1 | 2007 | 365 | 0.020 |
Why?
|
| Dietary Supplements | 1 | 2008 | 254 | 0.020 |
Why?
|
| Adult | 1 | 2015 | 7740 | 0.010 |
Why?
|
| GRB10 Adaptor Protein | 1 | 2001 | 5 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2001 | 23 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2001 | 22 | 0.010 |
Why?
|
| Precipitin Tests | 1 | 2001 | 47 | 0.010 |
Why?
|
| Glutathione Transferase | 1 | 2001 | 33 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2001 | 87 | 0.010 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2001 | 97 | 0.010 |
Why?
|
| Protein Structure, Tertiary | 1 | 2001 | 284 | 0.010 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2001 | 140 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2001 | 155 | 0.010 |
Why?
|
| Time Factors | 1 | 2001 | 1592 | 0.010 |
Why?
|